These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 24186885)

  • 1. Canagliflozin: Improving diabetes by making urine sweet.
    Vouyiouklis M
    Cleve Clin J Med; 2013 Nov; 80(11):683-7. PubMed ID: 24186885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
    Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
    Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
    Boyle LD; Wilding JP
    Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canagliflozin for the treatment of type 2 diabetes.
    Babu A
    Drugs Today (Barc); 2013 Jun; 49(6):363-76. PubMed ID: 23807940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
    Said S; Hernandez GT
    Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin: a novel treatment option for type 2 diabetes.
    Dietrich E; Powell J; Taylor JR
    Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nyirjesy P; Zhao Y; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
    Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
    Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Canagliflozin. For treating diabetes].
    Sabourin G
    Perspect Infirm; 2013; 10(3):59. PubMed ID: 23705284
    [No Abstract]   [Full Text] [Related]  

  • 15. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2014 May; 74(7):807-24. PubMed ID: 24831734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
    Nisly SA; Kolanczyk DM; Walton AM
    Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
    Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
    Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
    Freeman JS
    Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.